Piclidenoson is under clinical development by Can-Fite BioPharma and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData, Phase III drugs for Plaque Psoriasis (Psoriasis Vulgaris) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Piclidenoson’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Piclidenoson overview

Piclidenoson (CF-101) is under development for the treatment of Sjogren's syndrome, moderate-to-severe plaque psoriasis. The therapeutic candidate is formulated as tablet and administered through oral route and through topical route. The drug candidate comprises of IB-MECA as the active ingredient. It acts by targeting A3 adenosine receptor (A3AR). It was also under development for the treatment of noninfectious intermediate or posterior uveitis osteoarthritis, dry eye, Crohn's disease, rheumatoid arthritis, ocular hypertension, open-angle glaucoma, neuropathic pain, chemotherapy-induced peripheral neuropathy, coronavirus disease 2019 (COVID-19), and metastatic colorectal cancer.

Can-Fite BioPharma overview

Can-Fite BioPharma (Can-Fite), is a clinical stage drug development company that strives to develop small molecule drugs for the treatment of cancer and inflammatory diseases. The company’s pipeline products which are in phase II and III clinical development stage includes CF101, for rheumatoid arthritis and psoriasis; CF102, for hepatocellular carcinoma; and CF602, for erectile dysfunction. Can-Fite develops its products by harnessing its technology platform which is based on the Gi protein associates A3 adenosine receptor (A3AR). The company works in collaboration with pharmaceutical and biotechnology companies to develop its product portfolio. It has operations in Israel and the US. Can-Fite is headquartered in Petah Tikva, Israel.

For a complete picture of Piclidenoson’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.